• Brilinta found to reduce bleeding vs dual therapy pharmatimes
    April 01, 2020
    AstraZeneca has announced that the Phase IV independent TWILIGHT trial, Brilinta (ticagrelor) monotherapy reduced bleeding complications with no increased risk of ischaemic events in patients with diabetes undergoing percutaneous coronary intervention.
PharmaSources Customer Service